Sandrock Alfred
Officer, Director at VYGR; Head of Research & Development at BIIB
- Sold, on record
- $17.9M
- Dollars the filings state
- Form 4 sales
- 35
- Latest Apr 2, 2026
- Form 144 notices
- 9
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 144 notice VYGRNoticeFeb 10, 2026 2026
Filed to sell 12,192 shares ($46k)
Sandrock Alfred, Officer, Director
No 10b5-1 plan1x usual sizeFiling
- 2 Form 4 sale VYGRNo planFeb 10, 2026 same day
Sold 12,192 shares at $3.78 ($46k)
Sandrock Alfred, President and CEO
No 10b5-1 planSold 2.3% of holdings ($2M position)509,989 shares left1x usual sizeFollows a Form 144Filing
- 3 Form 144 notice VYGRNoticeFeb 18, 2026 +8 days
Filed to sell 11,732 shares ($40k)
Sandrock Alfred, Officer, Director
No 10b5-1 plan1x usual sizeFiling
- 4 Form 4 sale VYGRRoutineFeb 18, 2026 same day
Sold 11,732 shares at $3.41 ($40k)
Sandrock Alfred, President and CEO
10b5-1 planSold 2.3% of holdings ($1.7M position)498,257 shares left1x usual sizeFollows a Form 144Filing
- 5 Form 144 notice VYGRNoticeFeb 24, 2026 +6 days
Filed to sell 14,197 shares ($54k)
Sandrock Alfred, Officer, Director
No 10b5-1 plan1.2x usual sizeFiling
- 6 Form 4 sale VYGRRoutineFeb 24, 2026 same day
Sold 14,197 shares at $3.79 ($54k)
Sandrock Alfred, President and CEO
10b5-1 planSold 2.8% of holdings ($1.9M position)484,060 shares left1.2x usual sizeFollows a Form 144Filing
- 7 Form 144 notice VYGRNoticeApr 2, 2026 +37 days
Filed to sell 11,511 shares ($45k)
Sandrock Alfred, Officer, Director
No 10b5-1 plan1x usual sizeFiling
- 8 Form 4 sale VYGRRoutineApr 2, 2026 same day
Sold 11,511 shares at $3.87 ($45k)
Sandrock Alfred, President and CEO
10b5-1 planSold 2.4% of holdings ($1.9M position)472,549 shares left1x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (44)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Apr 3, 2026 | VYGR | President and CEO | Form 4 sale | 11,511 | $45k | 2.4% | Routine | SEC |
| Apr 2, 2026 | Apr 2, 2026 | VYGR | Officer, Director | Form 144 notice | 11,511 | $45k | Notice | SEC | |
| Feb 24, 2026 | Feb 26, 2026 | VYGR | President and CEO | Form 4 sale | 14,197 | $54k | 2.8% | Routine | SEC |
| Feb 24, 2026 | Feb 24, 2026 | VYGR | Officer, Director | Form 144 notice | 14,197 | $54k | Notice | SEC | |
| Feb 18, 2026 | Feb 20, 2026 | VYGR | President and CEO | Form 4 sale | 11,732 | $40k | 2.3% | Routine | SEC |
| Feb 18, 2026 | Feb 18, 2026 | VYGR | Officer, Director | Form 144 notice | 11,732 | $40k | Notice | SEC | |
| Feb 10, 2026 | Feb 11, 2026 | VYGR | President and CEO | Form 4 sale | 12,192 | $46k | 2.3% | No plan | SEC |
| Feb 10, 2026 | Feb 10, 2026 | VYGR | Officer, Director | Form 144 notice | 12,192 | $46k | Notice | SEC | |
| Apr 2, 2025 | Apr 4, 2025 | VYGR | President and CEO | Form 4 sale | 10,885 | $37k | 2.5% | No plan | SEC |
| Apr 2, 2025 | Apr 2, 2025 | VYGR | Officer, Director | Form 144 notice | 10,885 | $37k | Notice | SEC | |
| Feb 20, 2025 | Feb 24, 2025 | VYGR | President and CEO | Form 4 sale | 11,702 | $50k | 3.8% | No plan | SEC |
| Feb 20, 2025 | Feb 20, 2025 | VYGR | Officer, Director | Form 144 notice | 11,702 | $50k | Notice | SEC | |
| Feb 11, 2025 | Feb 12, 2025 | VYGR | President & CEO | Form 4 sale | 16,644 | $74k | 5.1% | No plan | SEC |
| Feb 11, 2025 | Feb 11, 2025 | VYGR | Officer, Director | Form 144 notice | 16,644 | $74k | Notice | SEC | |
| Apr 2, 2024 | Apr 3, 2024 | VYGR | President and CEO | Form 4 sale | 12,115 | $119k | 3.6% | No plan | SEC |
| Apr 2, 2024 | Apr 2, 2024 | VYGR | Officer, Director | Form 144 notice | 12,115 | $120k | Notice | SEC | |
| Feb 21, 2024 | Feb 22, 2024 | VYGR | President and CEO | Form 4 sale | 13,033 | $97k | 3.7% | No plan | SEC |
| Feb 21, 2024 | Feb 21, 2024 | VYGR | Officer, Director | Form 144 notice | 13,033 | $97k | Notice | SEC | |
| Apr 3, 2023 | Apr 5, 2023 | VYGR | President and CEO | Form 4 sale | 7,437 | $58k | 3.3% | No plan | SEC |
| Jun 7, 2021 | Jun 9, 2021 | BIIB | Head of Research & Development | Form 4 sale | 7,672 | $3.4M | 43.0% | Unusual | SEC |
| Nov 4, 2020 | Nov 6, 2020 | BIIB | EVP, Research & Development | Form 4 sale | 1,500 | $525k | 10.3% | Plan not stated | SEC |
| Feb 27, 2018 | Feb 28, 2018 | BIIB | EVP, Chief Medical Officer | Form 4 sale | 259 | $75k | 3.8% | Plan not stated | SEC |
| Feb 23, 2018 | Feb 27, 2018 | BIIB | EVP, Chief Medical Officer | Form 4 sale | 908 | $266k | 12.2% | Plan not stated | SEC |
| Feb 20, 2018 | Feb 21, 2018 | BIIB | EVP, Chief Medical Officer | Form 4 sale | 743 | $217k | 10.2% | Plan not stated | SEC |
| Feb 15, 2018 | Feb 20, 2018 | BIIB | EVP, Chief Medical Officer | Form 4 sale | 1,294 | $387k | 15.1% | Plan not stated | SEC |
| Apr 3, 2017 | Apr 4, 2017 | BIIB | EVP CMO Neuro & Neurodegenerat | Form 4 sale | 1,981 | $543k | 21.9% | Plan not stated | SEC |
| Mar 1, 2017 | Mar 3, 2017 | BIIB | EVP CMO Neuro & Neurodegenerat | Form 4 sale | 973 | $282k | 9.7% | Plan not stated | SEC |
| Feb 25, 2016 | Feb 26, 2016 | BIIB | EVP CMO Neuro & Neurodegenerat | Form 4 sale | 183 | $48k | 2.2% | Plan not stated | SEC |
| Feb 17, 2016 | Feb 19, 2016 | BIIB | EVP CMO Neuro & Neurodegenerat | Form 4 sale | 722 | $185k | 8.3% | Plan not stated | SEC |
| Feb 9, 2016 | Feb 10, 2016 | BIIB | EVP CMO Neuro & Neurodegenerat | Form 4 sale | 852 | $210k | 9.9% | Plan not stated | SEC |
| Dec 4, 2015 | Dec 7, 2015 | BIIB | EVP CMO Neuro & Neurodegenerat | Form 4 sale | 441 | $122k | 5.4% | Plan not stated | SEC |
| Mar 27, 2015 | Mar 30, 2015 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 430 | $185k | 4.8% | Plan not stated | SEC |
| Mar 2, 2015 | Mar 3, 2015 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 3,174 | $1.3M | 26.1% | Unusual | SEC |
| Feb 17, 2015 | Feb 18, 2015 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 418 | $163k | 2.7% | Plan not stated | SEC |
| Feb 10, 2015 | Feb 11, 2015 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 1,143 | $455k | 7.3% | Plan not stated | SEC |
| Feb 9, 2015 | Feb 10, 2015 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 856 | $341k | 5.5% | Plan not stated | SEC |
| Dec 4, 2014 | Dec 5, 2014 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 440 | $152k | 2.9% | Plan not stated | SEC |
| Mar 4, 2014 | Mar 5, 2014 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 3,171 | $1.1M | 17.1% | Plan not stated | SEC |
| Feb 26, 2014 | Feb 27, 2014 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 1,048 | $359k | 4.7% | Plan not stated | SEC |
| Feb 13, 2014 | Feb 14, 2014 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 425 | $134k | 1.9% | Plan not stated | SEC |
| Feb 11, 2014 | Feb 12, 2014 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 2,085 | $655k | 13.2% | Plan not stated | SEC |
| Dec 4, 2013 | Dec 5, 2013 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 439 | $126k | 3.1% | Plan not stated | SEC |
| Oct 22, 2013 | Oct 23, 2013 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 15,030 | $3.8M | 50.9% | Unusual | SEC |
| Sep 16, 2013 | Sep 18, 2013 | BIIB | Grp SVP, Chief Medical Officer | Form 4 sale | 9,820 | $2.4M | 40.4% | Unusual | SEC |